Compugen (CGEN) - Cash Flow Conversion Efficiency

Latest as of December 2022: 0.056x

Based on the latest financial reports, Compugen (CGEN) has a cash flow conversion efficiency ratio of 0.056x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA4.33 Million ≈ $11.60K USD) by net assets (ILA77.68 Million ≈ $208.26K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Compugen - Cash Flow Conversion Efficiency Trend (1999–2024)

This chart illustrates how Compugen's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CGEN total debt and obligations for a breakdown of total debt and financial obligations.

Compugen Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Compugen ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Berjaya Assets Bhd
KLSE:3239
0.032x
Daehan Steel
KO:084010
0.015x
Amcil Ltd
AU:AMH
0.012x
Xiongan Kerong Environment Technology Co Ltd
SHE:300152
-0.004x
X-Legend Entertainment Co Ltd
TW:4994
0.036x
Saksoft Limited
NSE:SAKSOFT
0.099x
Magnora ASA
OL:MGN
-0.110x
Security National Financial
NASDAQ:SNFCA
80.269x

Annual Cash Flow Conversion Efficiency for Compugen (1999–2024)

The table below shows the annual cash flow conversion efficiency of Compugen from 1999 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Compugen.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 ILA54.91 Million
≈ $147.22K
ILA49.60 Million
≈ $132.99K
0.903x +265.02%
2023-12-31 ILA65.56 Million
≈ $175.76K
ILA-35.89 Million
≈ $-96.21K
-0.547x -24.65%
2022-12-31 ILA77.68 Million
≈ $208.26K
ILA-34.11 Million
≈ $-91.46K
-0.439x -105.95%
2021-12-31 ILA106.69 Million
≈ $286.04K
ILA-22.75 Million
≈ $-60.99K
-0.213x +9.81%
2020-12-31 ILA119.78 Million
≈ $321.13K
ILA-28.32 Million
≈ $-75.92K
-0.236x +67.51%
2019-12-31 ILA38.32 Million
≈ $102.74K
ILA-27.89 Million
≈ $-74.77K
-0.728x -103.92%
2018-12-31 ILA37.24 Million
≈ $99.85K
ILA-13.29 Million
≈ $-35.63K
-0.357x +65.90%
2017-12-31 ILA29.30 Million
≈ $78.54K
ILA-30.66 Million
≈ $-82.19K
-1.046x -235.38%
2016-12-31 ILA63.52 Million
≈ $170.29K
ILA-19.82 Million
≈ $-53.13K
-0.312x -9.54%
2015-12-31 ILA89.90 Million
≈ $241.01K
ILA-25.61 Million
≈ $-68.65K
-0.285x -170.78%
2014-12-31 ILA105.97 Million
≈ $284.12K
ILA-11.15 Million
≈ $-29.89K
-0.105x +47.90%
2013-12-31 ILA31.89 Million
≈ $85.49K
ILA-6.44 Million
≈ $-17.26K
-0.202x +67.10%
2012-12-31 ILA17.67 Million
≈ $47.38K
ILA-10.85 Million
≈ $-29.08K
-0.614x -29.93%
2011-12-31 ILA19.58 Million
≈ $52.50K
ILA-9.25 Million
≈ $-24.80K
-0.472x -212.23%
2010-12-31 ILA28.29 Million
≈ $75.83K
ILA-4.28 Million
≈ $-11.47K
-0.151x +44.39%
2009-12-31 ILA27.40 Million
≈ $73.45K
ILA-7.45 Million
≈ $-19.98K
-0.272x +72.82%
2008-12-31 ILA10.00 Million
≈ $26.82K
ILA-10.01 Million
≈ $-26.84K
-1.001x -105.79%
2007-12-31 ILA17.29 Million
≈ $46.34K
ILA-8.41 Million
≈ $-22.54K
-0.486x -26.03%
2006-12-31 ILA25.74 Million
≈ $69.00K
ILA-9.93 Million
≈ $-26.63K
-0.386x -25.94%
2005-12-31 ILA36.25 Million
≈ $97.18K
ILA-11.11 Million
≈ $-29.78K
-0.306x -24.48%
2004-12-31 ILA49.57 Million
≈ $132.88K
ILA-12.20 Million
≈ $-32.71K
-0.246x -164.19%
2003-12-31 ILA59.81 Million
≈ $160.34K
ILA-5.57 Million
≈ $-14.94K
-0.093x +29.28%
2002-12-31 ILA68.88 Million
≈ $184.67K
ILA-9.08 Million
≈ $-24.33K
-0.132x -11.08%
2001-12-31 ILA80.06 Million
≈ $214.64K
ILA-9.50 Million
≈ $-25.46K
-0.119x -78.69%
2000-12-31 ILA92.51 Million
≈ $248.02K
ILA-6.14 Million
≈ $-16.46K
-0.066x +85.27%
1999-12-31 ILA12.79 Million
≈ $34.28K
ILA-5.76 Million
≈ $-15.45K
-0.451x --

About Compugen

TA:CGEN Israel Biotechnology
Market Cap
$199.11 Million
ILA74.27 Billion ILA
Market Cap Rank
#16686 Global
#204 in Israel
Share Price
ILA794.00
Change (1 day)
-1.07%
52-Week Range
ILA441.40 - ILA924.00
All Time High
ILA6613.00
About

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical tria… Read more